We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > SENSTEND

News List

Regent Pacific Receives HK$24.96 million After Clinical Trial Approval For FORTACIN(TM) Has Been Obtained prnasia
April 02, 2021
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce that the Group has received a payment of US$3.20 million (approximately HK$24.96 million) before deduction of PRC withholding ...
Regent Pacific Announces Key Progresses On FORTACIN(TM) / SENSTEND(TM) - Solution to Premature Ejaculation prnasia
January 05, 2021
Regent Pacific Group Limited, a specialist healthcare, wellness and life sciences investment group is pleased to announce several key updates of Fortacin™ / Senstend™, the first prescription solution to premature ejaculation (PE) that does not act on ...